From bispecific to multispecific antibodies: a highly promising field
Development of therapies modulating two or more targets is increasing rapidly despite facing a number of hurdles
Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
RAS inhibition: a game changer in pancreatic cancer?
Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients
Novel ADCs from Asia open new clinical opportunities
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
Access to targeted treatments for patients with CUP is still an issue
Studies underline that a tumour-agnostic approach may help improve treatment options
A new claudin 18.2-targeting approach appears promising in gastric cancers
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
Dual targeted therapy shows promise in mestastatic clear cell renal cell carcinoma
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
Combination improves endocrine response after CDK4/6 inhibition in ER-positive, HER2-negative advanced breast cancer
In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival
Data from two novel TEAD inhibitors provide the first evidence for the efficacy and safety of targeted treatments in mesothelioma
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity